Clinical Edge Journal Scan

Fertility preservation safe in young women with BC


 

Key clinical point: Women who were diagnosed with breast cancer (BC) at a young age and underwent fertility preservation (FP) did not experience any increased risk for disease-specific mortality or relapse.

Major finding: Compared with women who did not undergo FP, disease-specific mortality was similar in women who underwent hormonal FP (adjusted hazard ratio [aHR] 0.59; 95% CI 0.32-1.09) and nonhormonal FP (aHR 0.51; 95% CI 0.20-1.29). Hormonal (aHR 0.81; 95% CI 0.49-1.37) and nonhormonal (aHR 0.75; 95% CI 0.35-1.62) FP were associated with similar relapse or death rates in a subcohort of 723 women with complete relapse information.

Study details : Findings are from an analysis of a population-based nationwide cohort study including 1275 women of reproductive age (18-44 years old) who were diagnosed with BC, of which 425 women received hormonal (n = 367) or nonhormonal (n = 58) FP treatment.

Disclosures: This study was supported by the Swedish Cancer Society and other sources. Prof. Bergh declared receiving grants and personal fees from several sources.

Source: Marklund A et al. Relapse rates and disease-specific mortality following procedures for fertility preservation at time of breast cancer diagnosis. JAMA Oncol. 2022 (Aug 25). Doi: 10.1001/jamaoncol.2022.3677

Next Article: